Mylan says US FDA's generic user fee not discriminatory despite foreign inspection cost differential
This article was originally published in SRA
Executive Summary
US generic manufacturer Mylan believes that any claims of bias against foreign manufacturers within the US Food and Drug Administration's proposed generic drug user fee plan are "misplaced" and that the programme offers parity for all industry participants1. The US firm, seen as a "driving force" behind the proposal, also sees the programme securing American competitiveness and jobs.
You may also be interested in...
Prices Plunge As Xarelto Generics Arrive In India
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: